SRX.AX - Sirtex Medical Limited

ASX - ASX Delayed Price. Currency in AUD
33.55
0.00 (0.00%)
As of 4:11PM AEST. Market open.
Stock chart is not supported by your current browser
Previous Close0.00
Open33.52
Bid0.00 x 0
Ask0.00 x 0
Day's Range33.51 - 33.58
52 Week Range13.43 - 33.58
Volume619,777
Avg. Volume269,924
Market Cap1.894B
Beta (3Y Monthly)0.86
PE Ratio (TTM)45.96
EPS (TTM)0.73
Earnings DateN/A
Forward Dividend & YieldN/A (0.89%)
Ex-Dividend Date2017-09-26
1y Target Est33.60
  • Reuters27 days ago

    BRIEF-China Grand Pharmaceutical And Healthcare Announces Completion Of Sirtex Medical Acquisition

    Sept 20 (Reuters) - China Grand Pharmaceutical and Healthcare Holdings Ltd: * CHINA GRAND PHARMACEUTICAL AND HEALTHCARE ANNOUNCES COMPLETION OF ACQUISITION OF SIRTEX MEDICAL LIMITED * GROUP HAS BECOME ...

  • Reuterslast month

    BRIEF-Sirtex Medical Shareholders Vote In Favour Of Proposed Acquisition By Grand Pharma Sphere (Australia Bidco)

    Sept 10 (Reuters) - Sirtex Medical Ltd: * SHAREHOLDERS VOTED IN FAVOUR OF PROPOSED ACQUISITION OF SIRTEX MEDICAL BY GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LIMITED * HAS APPLIED TO FEDERAL COURT OF AUSTRALIA ...

  • Reuters2 months ago

    BRIEF-Sirtex Medical Notes Announcement By China Grand Pharmaceutical And Healthcare Holdings

    (Corrects source to Sirtex Medical, from China Grand Pharmaceutical and Healthcare) Aug 20 (Reuters) - SIRTEX MEDICAL: * NOTES AUG 17 ANNOUNCEMENT BY CHINA GRAND PHARMACEUTICAL AND HEALTHCARE HOLDINGS ...

  • Reuters3 months ago

    BRIEF-Sirtex Medical Says Federal Court of Australia Approved Despatching Of Scheme Booklet

    Aug 1 (Reuters) - Sirtex Medical Ltd: * CONTINUES TO UNANIMOUSLY RECOMMEND THAT SHAREHOLDERS VOTE IN FAVOUR OF CDH-CGP OFFER IN ABSENCE OF A SUPERIOR PROPOSAL * SCHEME MEETING WILL BE HELD ON 10 SEPT * ...

  • Reuters3 months ago

    Australia's Sirtex clears U.S. regulatory hurdle for Chinese buyout

    Liver cancer treatment maker Sirtex Medical said on Monday that the U.S. Federal Trade Commission cleared its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through. ...

  • Reuters3 months ago

    Australia's Sirtex clears U.S. regulatory hurdle for Chinese buyout

    July 16 (Reuters) - Liver cancer treatment maker Sirtex Medical said on Monday that the U.S. Federal Trade Commission cleared its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for ...

  • Reuters3 months ago

    BRIEF-Sirtex Medical Updates On Payment Of A$15.8 Mln Break Fee To Varian

    July 13 (Reuters) - Sirtex Medical Ltd: * PAYMENT OF A$15.8 MILLION BREAK FEE TO VARIAN * CONFIRMS HAS RECEIVED CASH REIMBURSEMENT FROM CDH-CGP EQUIVALENT TO AMOUNT PAID TO VARIAN Source text for Eikon: ...

  • Reuters3 months ago

    BRIEF-China Grand Pharmaceutical And Healthcare To Raise Up To HK$2.88 Bln Via Share Issuance

    July 4 (Reuters) - China Grand Pharmaceutical and Healthcare Holdings Ltd: * CO TO RAISE UP TO HK$2,879.12 MILLION BY ISSUING UP TO 553.7 MILLION RIGHTS SHARES * DEAL AT HK$5.20 PER RIGHTS SHARE * INTENDS ...

  • Reuters3 months ago

    Australia's Sirtex gets FIRB nod for Chinese buyout

    Liver cancer treatment maker Sirtex Medical said on Tuesday Australia's Foreign Investment Review Board (FIRB) had approved its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through. The company agreed last month to be taken over by Beijing-based CDH Investments and its partner, China Grand Pharmaceutical and Healthcare Holdings, which trumped a bid from U.S.-based Varian Medical Systems. Australia has proven an attractive destination for Chinese investment in the healthcare sector, with A$5.5 billion in deals agreed since 2015, according to a report published in January by accountancy firm KPMG.

  • Reuters3 months ago

    Australia's Sirtex gets FIRB nod for Chinese buyout

    Liver cancer treatment maker Sirtex Medical said on Tuesday Australia's Foreign Investment Review Board (FIRB) had approved its $1.4 billion buyout by a Chinese consortium, clearing a major hurdle for the deal to go through. The company agreed last month to be taken over by Beijing-based CDH Investments and its partner, China Grand Pharmaceutical and Healthcare Holdings, which trumped a bid from U.S.-based Varian Medical Systems. Australia has proven an attractive destination for Chinese investment in the healthcare sector, with A$5.5 billion in deals agreed since 2015, according to a report published in January by accountancy firm KPMG.

  • Reuters3 months ago

    BRIEF-Sirtex Medical Gets FIRB Approval

    July 3 (Reuters) - Sirtex Medical Ltd: * COMMONWEALTH TREASURER HAS NO OBJECTION TO ENTITY OWNED BY CDH FUND V, L.P. AND CHINA GRAND PHARMACEUTICAL AND HEALTHCARE ACQUIRING SIRTEX Source text for Eikon: ...

  • Reuters4 months ago

    Australia's Sirtex expects approval for Chinese buyout

    Australian liver cancer treatment maker Sirtex Medical Ltd expects its $1.4 billion buyout by a Chinese consortium to will win regulatory approval in Australia and the United States despite diplomatic tensions with China. The company agreed on Thursday to an offer from Beijing-based CDH Investments and its partner, China Grand Pharmaceutical and Healthcare Holdings, which trumped a bid from U.S.-based Varian Medical Systems.

  • Reuters4 months ago

    Australia's Sirtex expects approval for Chinese buyout

    Australian liver cancer treatment maker Sirtex Medical Ltd expects its $1.4 billion buyout by a Chinese consortium to will win regulatory approval in Australia and the United States despite diplomatic tensions with China. The company agreed on Thursday to an offer from Beijing-based CDH Investments and its partner, China Grand Pharmaceutical and Healthcare Holdings, which trumped a bid from U.S.-based Varian Medical Systems.

  • Reuters4 months ago

    Australia's Sirtex picks $1.4 bln Chinese bid over Varian offer

    Australia's Sirtex Medical has picked the highest bidder in a takeover battle for the liver cancer specialist, going with a $1.4 billion Chinese offer that trumped U.S. company Varian Medical Systems. The eleventh-hour bid from a consortium led by CDH Investments was 20 percent higher than Variant's and represents the latest move in a multibillion-dollar Australian healthcare shopping spree by Chinese investors.

  • Reuters4 months ago

    Australia's Sirtex picks $1.4 bln Chinese bid over Varian offer

    Australia's Sirtex Medical has picked the highest bidder in a takeover battle for the liver cancer specialist, going with a $1.4 billion Chinese offer that trumped U.S. company Varian Medical Systems. The eleventh-hour bid from a consortium led by CDH Investments was 20 percent higher than Variant's and represents the latest move in a multibillion-dollar Australian healthcare shopping spree by Chinese investors.

  • Reuters4 months ago

    Australia's Sirtex Medical accepts $1.4 bln offer from China's CDH Investments

    Liver cancer treatment firm Sirtex Medical Ltd said on Thursday its board has recommended an offer from China's CDH Investments to buy the firm for A$1.87 billion . The deal will result in the termination ...

  • Reuters4 months ago

    Australia's Sirtex Medical accepts $1.4 bln offer from China's CDH Investments

    June 14 (Reuters) - Liver cancer treatment firm Sirtex Medical Ltd said on Thursday its board has recommended an offer from China's CDH Investments to buy the firm for A$1.87 billion ($1.41 billion). The ...

  • Reuters4 months ago

    BRIEF-Sirtex Medical Enters Binding Scheme Implementation Deed With CDH Genetech And China Grand Pharma

    June 14 (Reuters) - Sirtex Medical Ltd: * TERMINATES VARIAN SCHEME & ENTERS INTO A BINDING SCHEME IMPLEMENTATION DEED WITH CDH GENETECH AND CHINA GRAND PHARMA * UNANIMOUSLY FORMED VIEW THAT CDH-CGP PROPOSAL ...

  • Insights on Varian’s Acquisition Deal with Sirtex Medical
    Market Realist4 months ago

    Insights on Varian’s Acquisition Deal with Sirtex Medical

    On January 30, Varian Medical Systems (VAR) entered into an agreement to acquire Australian company Sirtex Medical for $1.2 billion, at 28 Australian dollars per share. Sirtex Medical is a global life sciences company with a focus on interventional oncology therapies. Varian plans to fund the acquisition primarily through its 2018 revolving credit facility.

  • Reuters5 months ago

    BRIEF-China Grand Pharmaceutical And Healthcare To Participate In Takeover Offer For Sirtex Medical

    May 23 (Reuters) - China Grand Pharmaceutical and Healthcare Holdings Ltd: * CO TOGETHER WITH CDH GENETECH PROPOSES TO PARTICIPATE IN OFFER TO ACQUIRE SIRTEX MEDICAL * PURSUANT TO DEAL, CO WILL PROVIDE ...

  • Reuters5 months ago

    Varian says will not match Chinese bid for Australia's Sirtex

    Varian Medical Systems said it would not increase its offer to buy Australian liver cancer treatment provider Sirtex Medical Ltd after Sirtex on Tuesday said Chinese private equity firm CDH Investments had submitted a formal bid. CDH Investments this month made a last-minute offer of $1.4 billion, or A$33.60 per share, for Sirtex Medical, topping Varian Medical Systems' proposal days before the U.S. firm was set to seal a takeover deal.

  • Reuters5 months ago

    Australia's Sirtex Medicals gets binding offer from China's CDH

    Australian liver cancer treatment provider Sirtex Medical Ltd on Tuesday said it received a binding takeover offer from Chinese private equity firm CDH Investments. CDH Investments this month made a last-minute offer of $1.4 billion, or A$33.60 per share, for Sirtex Medical, topping Varian Medical Systems days before the U.S. firm was set to seal a takeover deal.

  • Reuters5 months ago

    Chinese firm makes last-minute $1.4 billion offer for Australia's Sirtex, trumps Varian

    SYDNEY/HONG KONG (Reuters) - Chinese private equity firm CDH Investments lobbed a last-minute $1.4 billion offer for Australian liver-cancer treatment firm Sirtex Medical (SRX.AX), trumping Varian Medical Systems (VAR.N) days before the U.S. firm was set to seal a takeover deal. CDH's A$33.60 ($25.33) surprise cash-per-share offer is fully a fifth higher than Varian's, at A$28 per share, and it lands amid a multibillion dollar shopping spree from Chinese interests in Australia's healthcare sector.

  • Reuters5 months ago

    Chinese firm makes last-minute $1.4 bln offer for Australia's Sirtex, trumps Varian

    SYDNEY/HONG KONG, May 4 (Reuters) - Chinese private equity firm CDH Investments lobbed a last-minute $1.4 billion offer for Australian liver-cancer treatment firm Sirtex Medical, trumping Varian Medical Systems days before the U.S. firm was set to seal a takeover deal. CDH's A$33.60 ($25.33) surprise cash-per-share offer is fully a fifth higher than Varian's, at A$28 per share, and it lands amid a multibillion dollar shopping spree from Chinese interests in Australia's healthcare sector.